Dear Dr. Eric Ménat, you should have checked the scientific facts before publishing your article in the last issue of the French magazine Santé, Corps et Esprit.1 While raising the importance of supporting patients’ immunity during chemotherapy, you quoted the research of my father, Mirko Beljanski, to promote RNA fragment products made of yeast, whose effectiveness is questionable.

I would like to remind you of the scientific facts that you seem to have ignored: the RNA fragments, on which my father based his research are not made of yeast, but of a non-pathogenic kind of bacteria, Escherichia coli K-12. They were also the subject of a clinical trial conducted at Cancer Treatment Centers of America (CTCA), which compared them to yeast-based RNA fragments that are sometimes found on the market.

The results were as follows: patients who received Beljanski’s RNA fragments saw an increase in their platelet count after each intake (FIG. 1), unlike yeast-based RNA fragments, whose effectiveness is questionable (FIG. 2):

Beljanski RNA fragments vs yeast-based RNA fragments

Beljanski’s RNA fragments vs yeast-based RNA fragments

For those who wish to learn more, the full results of the clinical trial with Beljanski’s RNA fragments were published in Biomed Central Cancer (Levin et al., BMC Cancer 2010, 10: 565), and are available online at www.beljanski.org

Do not be fooled, while the cost of yeast is cheaper compared to E. coli K-12 bacteria, a bacteria naturally produced in the human intestine, they do not yield the same results. Moreover, unlike Beljanski’s E. coli K-12 based RNA fragments, no serious toxicity studies have been performed on yeast based RNAs.


REFERENCES

1- Dr Eric Ménat « Cancer : voici comment devenir acteur de son traitement » revue Santé, Corps et Esprit. issue 10 – April 2017.